LEXIVA With Lower Dose Boosting Medication Ritonavir

Armen Hareyan's picture
Advertisement

LEXIVA

GlaxoSmithKline's HIV protease inhibitor LEXIVA (fosamprenavir calcium) may now be administered with 100mg of ritonavir, an agent that increases, or boosts, the level of protease inhibitors in the bloodstream.

The U.S. Food and Drug Administration approved once-daily LEXIVA 1400 mg with 100mg of ritonavir in adult patients who had not previously taken a protease inhibitor (PI). The approval was based on pharmacokinetic data demonstrating comparable blood plasma levels in healthy volunteers when LEXIVA was administered with the lower 100mg dose of ritonavir and the previously approved 200mg dose of ritonavir. This information has been added to the LEXIVA product label.

LEXIVA is indicated in combination with other antiretrovirals for the treatment of HIV infections. Ritonavir works with LEXIVA and other protease inhibitors to boost the medication level in the bloodstream making the protease inhibitor more effective in suppressing HIV. HIV medicines do not cure HIV infections/AIDS or prevent passing HIV to others.

"GlaxoSmithKline remains committed to improving patient care by making dosing options more convenient," said Mark Shaefer, Pharm. D., Director, Clinical Development at GlaxoSmithKline. "We understand that reducing the number of pills taken daily is an important consideration for patients starting HIV treatment."

Advertisement

The data supporting this label change were published in the February 2007 issue of Antimicrobial Agents and Chemotherapy.

LEXIVA Indication Statement and Background

LEXIVA is indicated for the treatment of HIV infection in combination with other antiretroviral medications. The following points should be considered when initiating therapy with LEXIVA plus ritonavir (LEXIVA/r) in protease inhibitor (PI)-experienced patients: the PI-experienced patient study was not large enough to reach a definitive conclusion that LEXIVA/r and lopinavir/ritonavir are clinically equivalent. Once-daily administration of LEXIVA plus ritonavir is not recommended for PI-experienced patients.

The recommended dosing for LEXIVA is:

-- Therapy naive adults

Advertisement